Patents by Inventor Walid M. Heneine
Walid M. Heneine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230226050Abstract: A method of achieving HIV viral remission in a patient in need thereof, comprising the steps of: after exposure of the patient to the HIV virus, administering an early antiretroviral therapy (eART) of therapeutically effective amounts of cabotegravir and rilpivirine long-acting antiretrovirals, and after eART suppression of the virus, discontinuing said early antiretroviral therapy.Type: ApplicationFiled: June 30, 2021Publication date: July 20, 2023Inventors: Michele B. DALY, Jose Gerardo GARCIA LERMA, Walid M. HENEINE, William Robert SPREEN, Peter Evan Owen WILLIAMS
-
Publication number: 20220265689Abstract: Disclosed is the use of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, and an integrase inhibitor prior to an exposure to a potential human immunodeficiency virus (HIV) infection, to protect the subject from the HIV infection. In some embodiments, a prophylactically effective amount of emtricitabine (FTC), a prophylactically effective amount of tenofovir or a tenofovir prodrug, such as tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), a prophylactically effective amount of the integrase inhibitor elvitegravir (EVG), and optionally cobicistat (COBI) are used to inhibit or prevent an HIV infection, wherein these agents are administered only prior to the exposure. In specific non-limiting examples, only one dose of the anti-retroviral viral agents is administered to a subject prior to the exposure.Type: ApplicationFiled: January 27, 2020Publication date: August 25, 2022Applicant: THE UNITED STATES OF AMERICA , as represented by the Secretary, Department of Health and HumanInventors: Jose Gerardo Garcia Lerma, Ivana Mabel Massud, Walid M. Heneine
-
Patent number: 11191763Abstract: Disclosed is the use of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, and an integrase inhibitor after exposure to a potential human immunodeficiency virus (HIV) infection to inhibit or prevent an HIV infection. In some embodiments, a pharmacologically effective amount of emtricitabine (FTC), a pharmacologically effective amount of tenofovir alafenamide (TAF) or tenofovir disproxil fumarate (TDF), a pharmacologically effective amount of the integrase inhibitor elvitegravir (EVG), and optionally cobistat (COBI) are used to inhibit or prevent an HIV infection, wherein these agents are administered only after a potential exposure to HIV. In specific non-limiting examples, only one or two doses of the anti-retroviral viral agents are administered to a subject after the potential exposure to HIV.Type: GrantFiled: March 19, 2018Date of Patent: December 7, 2021Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Jose Gerardo Garcia Lerma, Ivana Mabel Massud, Walid M. Heneine
-
Patent number: 11186651Abstract: Disclosed are monoclonal antibodies that specifically bind emtricitabine (FTC). Methods are also disclosed for using these antibodies to detect FTC in samples. In some embodiments, these methods are of use for determining if a subject is complying with a therapeutic or prophylactic protocol. In other embodiments, methods are disclosed for determining the dose of FTC to administer to a subject.Type: GrantFiled: July 10, 2019Date of Patent: November 30, 2021Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Timothy Clyde Granade, Ae Saekhou Youngpairoj, William Marshall Switzer, Walid M. Heneine, Chou-Pong Pau, HaoQiang Zheng, Jan Pohl
-
Publication number: 20210253738Abstract: Disclosed are monoclonal antibodies that specifically bind emtricitabine (FTC). Methods are also disclosed for using these antibodies to detect FTC in samples. In some embodiments, these methods are of use for determining if a subject is complying with a therapeutic or prophylactic protocol. In other embodiments, methods are disclosed for determining the dose of FTC to administer to a subject.Type: ApplicationFiled: July 10, 2019Publication date: August 19, 2021Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Timothy Clyde Granade, Ae Saekhou Youngpairoj, William Marshall Switzer, Walid M. Heneine, Chou-Pong Pau, HaoQiang Zheng, Jan Pohl
-
Patent number: 10793902Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided in an oligonucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCT reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: GrantFiled: December 20, 2017Date of Patent: October 6, 2020Assignee: The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
-
Patent number: 10738365Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: GrantFiled: June 2, 2014Date of Patent: August 11, 2020Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb, Xierong Wei
-
Publication number: 20200101072Abstract: Disclosed is the use of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, and an integrase inhibitor after exposure to a potential human immunodeficiency virus (HIV) infection to inhibit or prevent an HIV infection. In some embodiments, a pharmacologically effective amount of emtricitabine (FTC), a pharmacologically effective amount of tenofovir alafenamide (TAF) or tenofovir disproxil fumarate (TDF), a pharmacologically effective amount of the integrase inhibitor elvitegravir (EVG), and optionally cobistat (COBI) are used to inhibit or prevent an HIV infection, wherein these agents are administered only after a potential exposure to HIV. In specific non-limiting examples, only one or two doses of the anti-retroviral viral agents are administered to a subject after the potential exposure to HIV.Type: ApplicationFiled: March 19, 2018Publication date: April 2, 2020Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Jose Gerardo Garcia Lerma, Ivana Mabel Massud, Walid M. Heneine
-
Patent number: 10519518Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: GrantFiled: September 21, 2016Date of Patent: December 31, 2019Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Publication number: 20180195110Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided in an oligonucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCT reactions disclosed herein. Provided arc methods for the specific detection of several mutations in HIV' simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: ApplicationFiled: December 20, 2017Publication date: July 12, 2018Applicant: The Government of the United States of America, as Represented by the Secretary of Health and HumanInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
-
Patent number: 9879317Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: GrantFiled: February 17, 2012Date of Patent: January 30, 2018Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
-
Publication number: 20170058367Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: ApplicationFiled: September 21, 2016Publication date: March 2, 2017Inventors: Jeffrey A. Johnson, Walid M. Heneine
-
Patent number: 9476103Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: GrantFiled: October 21, 2013Date of Patent: October 25, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Publication number: 20160122835Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: ApplicationFiled: June 2, 2014Publication date: May 5, 2016Inventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb, Xierong Wei
-
Patent number: 9044509Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: GrantFiled: January 31, 2007Date of Patent: June 2, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Walid M. Heneine, Thomas M. Folks, Robert Janssen, Ronald Otten, Jose Gerardo Garcia Lerma
-
Publication number: 20140045174Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Publication number: 20130330726Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: ApplicationFiled: February 17, 2012Publication date: December 12, 2013Applicant: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
-
Patent number: 8592146Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: GrantFiled: September 4, 2012Date of Patent: November 26, 2013Assignee: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Publication number: 20120329041Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: ApplicationFiled: September 4, 2012Publication date: December 27, 2012Applicant: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Patent number: 7691572Abstract: Assays and kits for the detection of phenotypic resistance of a retrovirus to reverse transcriptase inhibitor-drugs in a biological sample. The assays are based on the direct analysis of the susceptibility of retroviral reverse transcriptase to inhibition by a reverse transcriptase inhibitor drug. The enzymatic activity of the reverse transcriptase is determined by measuring the DNA product produced when an RNA template and a first complementary DNA primer from a suitable region of the encephalomyocarditis virus genome are incubated with a biological sample containing reverse transcriptase in the presence of the drug to which resistance is being determined. The DNA product is amplified and detection of the amplified DNA indicates resistance to the drug employed in the assay. Detection of relatively greater amounts of amplified DNA when certain drugs are used indicates the presence of multiple nucleoside analog resistant strains or mutations.Type: GrantFiled: February 9, 2005Date of Patent: April 6, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Walid M. Heneine, Gerardo Garcia-Lerma, Shinji Yamamoto, William M. Switzer, Thomas M. Folks